started to enter the oversold territory..be patient..

After Dato Karim acquired major share in Kpower in 2019, then everything change..become the profit making company since then..

0.005 up to 0.305..and see tomorrow, maybe another limit up..if it does happen then the profit would be 12000% in just 2 days..chill..

the starting price for warrant is 0.005..so those who bought before ex date would have enjoyed 6000% of profit by now..

he has gone..

AnsonLiew u always heard false news..i feel sorry for u..

add me too 0184015966 thanks chill..

rm8

buy tp8

please add me too

selamat hari rayaaa

dpharma got high liquidity..potential for more capital gain..

TO price up 7 bids

last chance..after this rocket!

profitgrow tries to create panic selling so that he can collect lower price...sorry bro no chance..haha

normal profit taking in the afternoon..

haha!

last time also people talk about trap trap trap to glove counter..now gone already after it goes up like crazy..

dont listen to the naysayers...perseverance and patient are the key to profit..

everytime u wait, its getting higher..

nice ladder..

huatt huatt

the market is insane.. nothing is impossible now..my TP 7 for dpharma

yes. dont wait until the vaccine is out it will be too late..

steady uptrend !

yes, thats what i anticipated..

everybody is looking to buy low, but no chance..it ll increase more..n even higher with vaccine positive news..

correct, this is not a penny stock..nothing to be afraid of, the trend is gonna change soon..

get ready to accumulate more..

buy on dip..

Pfizer Inc (N:PFE), Novavax Inc (O:NVAX), Britian's AstraZeneca Plc (L:AZN) are other few drug makers that received funding from BARDA for coronavirus vaccine development.

A Phase 3 study, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, will begin on July 27 and involve about 30,000 participants, according to the company.

The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate.

(Reuters) - Moderna Inc (O:MRNA) said on Sunday it has received an additional $472 million (369.1 million pounds) from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.

A vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. Their Phase I/II trial, reported on July 20 in the journal Lancet, found that the vaccine was safe, causing no severe side effects. It raised antibodies against the coronavirus as well as other immune defenses. The vaccine is now in a Phase II/III trial in England, as well as Phase III trials in Brazil and South Africa. The project may deliver emergency vaccines by October. AstraZeneca has said their total manufacturing capacity for the vaccine, if approved, stands at two billion doses.

https://edition.cnn.com/2020/07/24/health/moderna-vaccine-barney-graham-gupta/index.html

Russia’s first vaccine against the novel coronavirus is ready, a government official said on Tuesday.
Ruslan Tsalikov, the first deputy defense minister, said two groups of volunteers have successfully completed clinical trials, with all of them having “built up immunity.”
“At the time of discharge, all the volunteers, without exception, built up immunity to the coronavirus and felt well. Thus, the first domestic vaccine against a new coronavirus infection is ready,” he said in an interview with AiF newspaper.
The vaccine, he said, was jointly developed by the Gamaleya National Research Centre for Epidemiology and Microbiology and the Main Military Clinical Burdenko Hospital.
Tsalikov added that the Russian military has “significant scientific potential and extensive experience” in vaccine development, citing as an example its contributions to developing a vaccine against the Ebola virus.
Production approval in August
Russian companies may get the go-ahead for mass production of the COVID-19 vaccine by August, another official said.
Kirill Dmitriyev, head of the Russian Direct Investment Fund (RDIF), said the next phase of clinical trials will end on Aug. 3, after which the third phase will be launched in Russia, Turkey, the UAE, and Africa.
“We expect approval from regulatory bodies in the Russian Federation in August, and immediately after that we plan to start mass production at the sites of the RDIF’s R-Pharm and Alium companies. We expect approval in other partner countries in September,” he said in a statement.
The official said Russia aims to produce 200 million doses of the vaccine by the end of the year in partnership with five other countries, which he did not name.
According to Dmitriyev, 30 million doses will be made in Russia and the rest in the other countries.
He added that Russia also plans to produce the vaccine being jointly developed by the Oxford University and pharmaceutical company AstraZeneca.
The Russian vaccine will be delivered together with a unique patented test that identifies special antibodies in the human body that attack the crown-like spikes of the coronavirus, the official said.
“I was myself inoculated with the Russian vaccine. I developed a stable immunity after 20 days, before getting the second maintenance dose, which should extend the immunity to two years,” he said.
Meanwhile, the daily figure of new coronavirus cases in Russia remained below 6,000 on Tuesday.
As many as 5,842 more infections raised the country’s total count to 783,328, with fatalities now over 12,500 and recoveries exceeding 562,000.

Phase three trials should be completed in about three months. In the meantime, they are in the final stages of approval,” he was quoted as saying.
Get the latest insights and analysis from our Global Impact newsletter on the big stories originating in China.

The vaccine candidate was jointly developed by the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products – subsidiaries of the SinoPharm unit, China National Biotec Group (CNBG).
Liu said the two institutes had built P3-level production facilities to ensure they had the capacity for large-scale production if the next phase was successful.

A coronavirus vaccine candidate developed by a Chinese pharmaceutical company could be ready for use by the end of this year, state media reported.
Liu Jingzhen, chairman of China National Pharmaceutical Group (SinoPharm), told state broadcaster CCTV on Tuesday that SinoPharm started phase three clinical trials in late June and the product was expected to enter the market by the end of the year.

yeay

common ar, dont gaduh2..u invest or not the covid19 is happening, take the chance if u wanna make money, if otherwise.. its all yours, ur money, nobody would force u..

even if vaccine is succesfully produced, the glove is still heavily used for the vaccination process to all societies..no worry.. the medical glove usage is still relevant..

not if u set cut loss..

profit taking new buyer who optimistic on market outlook for next week..